Press Releases

Email Alerts

Feb 10, 2017

Biostage Announces $8.0 Million Public Offering

Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Photos 1
Jan 6, 2017

Biostage to Present at Biotech Showcase™ 2017

- Presentation with Live Webcast on Monday, January 9th at 2:30 p.m. PT -

Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Photos 1
Dec 6, 2016

Biostage to Participate at the 2016 World Stem Cell Summit and RegMed Capital Conference

- CEO, Jim McGorry, to participate in presentation and panel discussion on Wednesday, December 7th at 2:00 PM ET -

Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Photos 1
Dec 1, 2016

Biostage Receives FDA Orphan Drug Designation for Cellspan™ Esophageal Implant

Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Photos 1
Nov 22, 2016

Nasdaq Provides Biostage with 180-day Period in Which to Regain Compliance with $1.00 Minimum Closing Bid Price Rule

- No immediate effect on the Company's Nasdaq listing or the trading of its common stock -

Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Photos 1

Show per page